Powered by RND

Derms on Drugs

Scholars in Medicine
Derms on Drugs
Latest episode

Available Episodes

5 of 16
  • Melanoma, Pre-Menstrual Rashes, Dermatomyositis and more
    Produced by ⁠Scholars in Medicine.comTune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo? Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!In This Episode:Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?Dermatomyositis: Consequences of misdiagnosis and delayed diagnosisVitiligo: Could hydroxychloroquine be a game-changer over NBUVB?Skin Inflammation: A key driver of food allergyPemphigoid: Insights into immunotherapy-induced casesPremenstrual Rashes: Managing flares in atopic,1.  Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.2.  Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis3.  Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial4.  Skin damage signals mediate allergic sensitization to spatially unlinked antigen5.  Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid6.  The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review7.  Nickel contact allergy and menstrual cycle8.  Autoimmune progesterone dermatitis: Update and insights
    --------  
    52:01
  • Radiation Therapy for Skin Cancer - Dermatology Office Appropriate or Too Hot to Handle?
    Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT could light up your approach to patient care—or leave you glowing in the dark.#Dermatology #SkinCancer #IGSRT #RadiationTherapy #DermEducation1.  Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasoundguided superficial radiotherapy, a multiinstitutional study ScholarsInMedicine.com2.  The Role of Image-Guided Superficial Radiation Therapy in the Treatment of Nonmelanoma Skin Cancer3.  Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study
    --------  
    53:53
  • SCC Scares, Lichen Planus Cancer Risks, CSU Breakthroughs, Psoriasis Wins, Chemo Hacks, and HS Itch Relief
    Buckle up for a whirlwind tour of the hottest dermatology literature. This week, we’ve got the deets on:Cutaneous squamous cell carcinoma: What predicts when it'll go rogue and metastasize? Spoiler: It’s not just bad vibes.Oral lichen planus: Turns out, its cancer risk is sneakier than a derm resident dodging clinic.Remibrutinib for CSU: The first oral game-changer for chronic spontaneous urticaria. Hives, meet your match!Psoriasis biologics: Which systemic treatments keep infections at bay? We’ve got the lowdown.Chemo’s conundrum: One bizarre trick to stop a cutaneous side effectsHidradenitis suppurativa itch: Dermeleve’s here to make HS patients stop scratching and start living.Join us for laughs, learning, and maybe a few gasps as we unpack the science that’s got the derm world buzzing. Perfect for dermatologists, PAs, NPs, pharma folks, and students who live for skin-deep insights. Subscribe, share, and let’s make dermatology lit!  #DermatologyPodcast #DermLifeScholarsinMedicine.com⁠
    --------  
    50:07
  • Deep Dive into Gene Expression Profiling
    When a pathology report says 'melanoma,' the stakes are high. How confident are you in the diagnosis? Should you order gene expression profiling for better prognostic insights—or is it overrated? Join the Derms on Drugs as we dig into the challenges of melanoma diagnosis and management. This week, we’re thrilled to feature Dr. Whitney High from the University of Colorado, the best-of-the-best dermatopathology expert, to share evidence-based answers with the Derms on Drugs flare our listeners expect.  Derms on Drugs is brought to you by ⁠⁠Scholars in Medicine.⁠Resource links for this episode are available at ⁠Scholars in Medicine⁠.1.  Society of Surgical Oncology Consensus Statement: Assessing the Evidence for and Utility of Gene Expression Profiling of Primary Cutaneous Melanoma2.  31-GEP (DecisionDx): a review of clinical utility and performance in a Mayo Clinic cohort3.  CLO25-055: Metastasis-Free Survival Prediction With the 40-Gene Expression Profile Test in Patients With Cutaneous Squamous Cell Carcinoma Risk Stratified According to the National Comprehensive Cancer Network Guidelines4.  CGE25-104: The 31-GEP Identifies Patients With Early-Stage I-IIA Cutaneous Melanoma at High Risk of Melanoma-Specific and Overall Mortality
    --------  
    47:55
  • Dupixent and CTCL Risk: What Dermatologists Need to Know
    Does Dupixent raise the risk of cutaneous T-cell lymphoma (CTCL) in atopic dermatitis patients? It’s the burning question gripping dermatology—and we’ve got answers. Join the Derms on Drugs team as we unpack the latest with Dr. Shamir Geller, who runs a CTCL clinic at Memorial Sloan Kettering and published the first data that truly helps us understand if there is a Dupixent - CTCL link. Plus, we dive into CTCL survival stats and must-know updates for practicing dermatologists. Essential listening for anyone who is taking care of dermatology patients.Derms on Drugs is brought to you by Scholars in Medicine.Guest: Shamir Geller, MD Associate Attending Physician Dermatology Service, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, NY Associate Professor of Clinical Dermatology, Department of Dermatology, Weill Cornell Medicine, New York, NY I’m a dermatologist interested mainly in cutaneous lymphoma. During my cutaneous oncology fellowship at Memorial Sloan Kettering Cancer Center (MSK) between the years 2016-2019, I became a cutaneous lymphoma enthusiast, working at MSK multi-disciplinary cutaneous lymphoma clinic. Under the mentorship of expert faculty in dermatology, oncology, and pathology, I was able to master the art of integrating clinical findings, histopathologic features, clinical laboratory data, and molecular characteristics to reach to the diagnosis and most suitable treatment. After my fellowship I was appointed as an attending physician in the cutaneous lymphoma clinic at Tel Aviv Sourasky Medical Center in Israel and provided care for patients with cutaneous lymphomas while continuing to pursue research in the field. In early 2023 I returned to New York to the cutaneous lymphoma clinic at MSKCC as an associate attending. Other than clinical work and research, I dedicate a large portion of my time and effort to teaching and mentoring students, residents, fellows and visiting physicians. My research projects have been published in the leading dermatology, hematology and oncology journals and I’ve been invited and chosen to present my works in numerous regional, national and international conferences (ASH, USCLC, WCCL, EORTC, SID, AAD, EADV and others). I’m frequently asked to peer-review manuscripts on lymphomas of the skin and I also assist the cutaneous lymphoma foundation (CLF) with the preparation of patients’ education materials and lectures. Resource links for this episode available at ⁠Scholars in Medicine⁠.Integrative epidemiology and immunotranscriptomics uncover a risk and potential mechanism for cutaneous lymphoma unmasking or progression with dupilumab therapyOverall and Cause-Specific Mortality Among Patients With Cutaneous T-Cell Lymphoma in the United StatesDiagnosis of cutaneous T-cell lymphoma following exposure to biologic agents for atopic dermatitis: A retrospective cohort study from a single tertiary cancer center
    --------  
    42:04

More Health & Wellness podcasts

About Derms on Drugs

Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology. It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful. Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
Podcast website

Listen to Derms on Drugs, ZOE Science & Nutrition and many other podcasts from around the world with the radio.net app

Get the free radio.net app

  • Stations and podcasts to bookmark
  • Stream via Wi-Fi or Bluetooth
  • Supports Carplay & Android Auto
  • Many other app features
Social
v7.16.2 | © 2007-2025 radio.de GmbH
Generated: 5/5/2025 - 7:20:13 AM